DE602005020076D1 - Herstellung von TNFR-Fc - Google Patents

Herstellung von TNFR-Fc

Info

Publication number: DE602005020076D1
Authority: DE; Germany
Prior art keywords: tnfr; preparation
Prior art date: 2004-08-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

DE602005020076T

Other languages

English (en)

Inventor

Denis Drapeau

Yen-Tung Luan

James R Mercer

Wenge Wang

Daniel R Lasko

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth Research Ireland Ltd

Original Assignee

Wyeth Research Ireland Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-27

Filing date

2005-08-26

Publication date

2010-04-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005020076(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-26 Application filed by Wyeth Research Ireland Ltd filed Critical Wyeth Research Ireland Ltd

2010-04-29 Publication of DE602005020076D1 publication Critical patent/DE602005020076D1/de

Status Active legal-status Critical Current

2025-08-27 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions

DE602005020076T 2004-08-27 2005-08-26 Herstellung von TNFR-Fc Active DE602005020076D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60537904P	2004-08-27	2004-08-27

Publications (1)

Publication Number	Publication Date
DE602005020076D1 true DE602005020076D1 (de)	2010-04-29

Family

ID=35500648

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE602005017285T Active DE602005017285D1 (de)	2004-08-27	2005-08-26
DE602005020076T Active DE602005020076D1 (de)	2004-08-27	2005-08-26	Herstellung von TNFR-Fc

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE602005017285T Active DE602005017285D1 (de)	2004-08-27	2005-08-26

Country Status (38)

Country	Link
US (1)	US7300773B2 (de)
EP (2)	EP1992697B1 (de)
JP (3)	JP2008511330A (de)
KR (1)	KR100988451B1 (de)
CN (2)	CN101061231B (de)
AR (2)	AR050537A1 (de)
AT (2)	ATE461285T1 (de)
AU (1)	AU2005280036B2 (de)
BR (1)	BRPI0514694B8 (de)
CA (1)	CA2578138C (de)
CL (1)	CL2017000577A1 (de)
CR (2)	CR8998A (de)
CY (2)	CY1109721T1 (de)
DE (2)	DE602005017285D1 (de)
DK (2)	DK1781802T3 (de)
EC (1)	ECSP077354A (de)
EG (1)	EG26922A (de)
ES (2)	ES2341390T3 (de)
GT (2)	GT200500234A (de)
HK (2)	HK1099941A1 (de)
HN (1)	HN2005000485A (de)
HR (2)	HRP20100011T1 (de)
IL (1)	IL181588A (de)
MX (1)	MX2007002381A (de)
MY (1)	MY137803A (de)
NO (1)	NO344785B1 (de)
NZ (1)	NZ579208A (de)
PE (2)	PE20100448A1 (de)
PL (2)	PL1992697T3 (de)
PT (2)	PT1992697E (de)
RS (2)	RS51255B (de)
RU (1)	RU2458988C2 (de)
SI (2)	SI1781802T1 (de)
SV (1)	SV2006002211A (de)
TW (1)	TWI364458B (de)
UA (1)	UA89383C2 (de)
WO (1)	WO2006026447A2 (de)
ZA (1)	ZA200701672B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI384069B (zh)	2004-08-27	2013-02-01	Pfizer Ireland Pharmaceuticals	多胜肽之製法
US7335491B2 (en)	2004-08-27	2008-02-26	Wyeth Research Ireland Limited	Production of anti-abeta
ES2776657T3 (es)	2005-06-14	2020-07-31	Amgen Inc	Formulaciones de proteínas autotamponantes
PE20070796A1 (es) *	2005-10-24	2007-08-15	Wyeth Corp	Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) *	2005-11-02	2007-10-04	Lee Gene W	Methods for adapting mammalian cells
DK2041270T3 (da) *	2006-07-13	2014-01-27	Wyeth Llc	Fremstilling af glycoproteiner
MX2009004519A (es) *	2006-11-03	2009-05-12	Wyeth Corp	Sustancias que inhiben la glucolisis en un cultivo de celulas.
CA2668771C (en) *	2006-11-08	2016-03-15	Wyeth	Rationally designed media for cell culture
KR20090127326A (ko) *	2007-03-02	2009-12-10	와이어쓰	폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
DK2154244T3 (en)	2007-04-26	2017-06-12	Chugai Pharmaceutical Co Ltd	CELL CULTIVATION PROCEDURE WHEN AN ACID-ENRICHED MEDIUM IS USED
US8039231B2 (en) *	2008-04-17	2011-10-18	Wyeth Llc	Methods for enhanced production of bone morphogenetic proteins
US20110111495A1 (en) *	2008-04-18	2011-05-12	Shanghai Cp Guojian Pharmaceutical Co. Ltd	Concentrated medium and its usage
US8318416B2 (en)	2008-08-08	2012-11-27	Biogen Idec Ma Inc.	Nutrient monitoring and feedback control for increased bioproduct production
HUE048980T2 (hu)	2009-08-11	2020-08-28	Hoffmann La Roche	Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban
WO2011068993A1 (en) *	2009-12-02	2011-06-09	Acceleron Pharma Inc.	Compositions and methods for increasing serum half-life of fc fusion proteins.
CA2797140C (en)	2010-04-26	2018-01-23	Novartis Ag	Improved cell culture medium
LT2563906T (lt)	2010-04-26	2018-02-26	Novartis Ag	Cho ląstelių kultivavimo būdas
WO2012023085A1 (en)	2010-08-20	2012-02-23	Wyeth Llc	Cell culture of growth factor-free adapted cells
EP2640483A1 (de) *	2010-11-15	2013-09-25	Biogen Idec Inc.	Aneicherung und konzentrierung ausgewählter produktisoformen durch überlastete bindung und elutionschromatographie
KR101591671B1 (ko)	2011-04-29	2016-02-04	바이오콘 리서치 리미티드	항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
WO2012170938A1 (en)	2011-06-08	2012-12-13	Acceleron Pharma Inc.	Compositions and methods for increasing serum half-life
JP6220789B2 (ja)	2011-10-18	2017-10-25	コヒラス・バイオサイエンシズ・インコーポレイテッド	糖およびポリオールの組合せによって安定化されたエタネルセプト製剤
US10485869B2 (en)	2011-10-18	2019-11-26	Coherus Biosciences, Inc.	Etanercept formulations stabilized with meglumine
ES2784146T3 (es)	2011-10-21	2020-09-22	Pfizer	Adición de hierro para mejorar el cultivo celular
AU2013223801B2 (en) *	2012-02-22	2016-02-25	Zoetis Services Llc	Tumour necrosis factor receptor fusion proteins and methods of using the same
BR112015000203A2 (pt)	2012-07-09	2017-06-27	Coherus Biosciences Inc	formulações de etanercept que exibem redução marcada em partículas sub-visíveis
CN104902914B (zh)	2012-09-11	2019-01-01	科荣生生物科学公司	高纯度和优异产量的正确折叠的依那西普
US9217168B2 (en)	2013-03-14	2015-12-22	Momenta Pharmaceuticals, Inc.	Methods of cell culture
RS59328B1 (sr)	2013-03-26	2019-10-31	Coherus Biosciences Inc	Postupak za proizvodnju proteina
KR101439195B1 (ko)	2013-04-18	2014-09-12	동아대학교 산학협력단	에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정
US11390663B2 (en)	2013-10-11	2022-07-19	Regeneron Pharmaceuticals, Inc.	Metabolically optimized cell culture
SG10201800772TA (en) *	2013-10-11	2018-03-28	Regeneron Pharma	Metabolically optimized cell culture
ES2784775T3 (es) *	2014-01-30	2020-09-30	Coherus Biosciences Inc	Medios de perfusión
EP3102589A1 (de)	2014-02-04	2016-12-14	Biogen MA Inc.	Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen
MX2017006997A (es)	2014-12-01	2017-10-16	Amgen Inc	Proceso para manipular el nivel de contenido de glicano de una glicoproteina.
KR102007930B1 (ko)	2014-12-31	2019-08-06	주식회사 엘지화학	재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) *	2015-03-20	2016-07-20	广东东阳光药业有限公司	一种cho细胞收获液的前处理方法
CA3208857A1 (en) *	2015-04-01	2016-10-06	Boehringer Ingelheim International Gmbh	Cell culture medium
KR101936049B1 (ko) *	2015-10-15	2019-01-08	(주)알테오젠	IgG Fc 도메인을 가지는 융합 단백질의 생산방법
MX2019004580A (es)	2016-10-21	2019-08-12	Amgen Inc	Formulaciones farmaceuticas y metodos para prepararlas.
CN110484487A (zh) *	2019-08-21	2019-11-22	安徽欣乐生物技术有限公司	一种适用于cho细胞培养用无蛋白培养基及其培养方法
EP4267717A1 (de)	2020-12-22	2023-11-01	Amgen Inc.	Zellkulturverfahren
CN115073607A (zh) *	2021-03-12	2022-09-20	上海康岱生物医药技术股份有限公司	Tnfr2与baff受体的融合蛋白
CN114480492B (zh) *	2022-01-28	2023-04-21	景泽生物医药(合肥)股份有限公司	一种重组人抗体融合蛋白的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en) *	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en)	1983-01-19	1987-12-15	Genentech, Inc.	Polycistronic expression vector construction
AU2353384A (en)	1983-01-19	1984-07-26	Genentech Inc.	Amplification in eukaryotic host cells
GB8308235D0 (en) *	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5672502A (en) *	1985-06-28	1997-09-30	Celltech Therapeutics Limited	Animal cell culture
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US6048728A (en) *	1988-09-23	2000-04-11	Chiron Corporation	Cell culture medium for enhanced cell growth, culture longevity, and product expression
DE68925971T2 (de) *	1988-09-23	1996-09-05	Cetus Oncology Corp	Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US6291159B1 (en) *	1989-05-16	2001-09-18	Scripps Research Institute	Method for producing polymers having a preselected activity
NZ235148A (en) *	1989-09-05	1991-12-23	Immunex Corp	Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) *	1989-09-05	1997-02-25	Immunex Corporation	Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) *	1989-09-05	1995-03-07	Immunex Corporation	DNA encoding tumor necrosis factor-α and -β receptors
JPH0396383A (ja)	1989-09-08	1991-04-22	Riso Kagaku Corp	画像形成装置
ATE194384T1 (de)	1989-09-12	2000-07-15	Hoffmann La Roche	Tnf-bindende proteine
ES2118066T3 (es) *	1989-10-05	1998-09-16	Optein Inc	Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) *	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5538983A (en) *	1990-05-16	1996-07-23	The Rockefeller University	Method of treating amyloidosis by modulation of calcium
US5156964A (en) *	1990-08-16	1992-10-20	Cetus Corporation	Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) *	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en)	1990-10-05	1990-11-21	Gorman Scott David	Antibody preparation
GB9022545D0 (en)	1990-10-17	1990-11-28	Wellcome Found	Culture medium
GB2251249B (en)	1990-12-28	1995-06-21	Mogam Biotech Res Inst	High-density medium for animal cell culture
GB9118664D0 (en) *	1991-08-30	1991-10-16	Celltech Ltd	Cell culture
US5447851B1 (en) *	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3504963B2 (ja)	1993-10-22	2004-03-08	智靖羅	抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US6310185B1 (en) *	1994-03-08	2001-10-30	Memorial Sloan Kettering Cancer Center	Recombinant human anti-Lewis Y antibodies
US5856179A (en) *	1994-03-10	1999-01-05	Genentech, Inc.	Polypeptide production in animal cell culture
US5589154A (en) *	1994-11-22	1996-12-31	Rutgers, The State University Of New Jersey	Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US5721121A (en) *	1995-06-06	1998-02-24	Genentech, Inc.	Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) *	1995-06-06	2003-12-02	Genetech, Inc.	Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) *	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
JP4306813B2 (ja) *	1995-09-19	2009-08-05	アスビオファーマ株式会社	動物細胞の新規培養方法
US20020012991A1 (en)	1997-04-07	2002-01-31	Florence Chua Nee Ho Kit Fong	Cell culture media for enhanced protein production
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
CA2354862A1 (en)	1998-10-19	2000-04-27	Yeda Research And Development Co. Ltd.	Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en)	2001-02-08	2010-08-21	Wyeth Corp	Modified and stabilized gdf propeptides and uses thereof
ES2437875T3 (es)	2001-04-30	2014-01-14	Eli Lilly And Company	Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE60229051D1 (de)	2001-04-30	2008-11-06	Lilly Co Eli	Humanisierte antikörper
AU2002316230A1 (en)	2001-06-13	2002-12-23	Genentech, Inc.	Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
IL163525A0 (en)	2002-02-21	2005-12-18	Wyeth Corp	A follistatin domain containing protein
WO2003072714A2 (en)	2002-02-21	2003-09-04	Wyeth	Follistatin domain containing proteins
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
HUE030806T2 (hu)	2002-05-02	2017-05-29	Wyeth Holdings Llc	Calicheamicin származék-hordozó konjugátumok
AR047392A1 (es)	2002-10-22	2006-01-18	Wyeth Corp	Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
US7335491B2 (en)	2004-08-27	2008-02-26	Wyeth Research Ireland Limited	Production of anti-abeta
TWI384069B (zh)	2004-08-27	2013-02-01	Pfizer Ireland Pharmaceuticals	多胜肽之製法

2005
- 2005-08-25 US US11/213,633 patent/US7300773B2/en active Active
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 EP EP08005732A patent/EP1992697B1/de not_active Revoked
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 EP EP05791482A patent/EP1781802B1/de not_active Revoked
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de active Active
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en active Active
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es active Active
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en active Application Filing
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es active Active
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de active Active
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 CA CA2578138A patent/CA2578138C/en active Active
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko active IP Right Grant
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
- 2007-07-16 HK HK07107585.9A patent/HK1099941A1/xx not_active IP Right Cessation
- 2007-07-16 HK HK09102060.2A patent/HK1121497A1/xx not_active IP Right Cessation
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-01-11 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja active Active
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown

Also Published As

Publication number	Publication date
ZA200701672B (en)	2012-04-24
BRPI0514694B8 (pt)	2021-05-25
ATE461285T1 (de)	2010-04-15
JP2012095672A (ja)	2012-05-24
US20060121569A1 (en)	2006-06-08
HRP20100011T1 (hr)	2010-02-28
CN102876761A (zh)	2013-01-16
CA2578138A1 (en)	2006-03-09
ATE446376T1 (de)	2009-11-15
DK1992697T3 (da)	2010-05-17
MY137803A (en)	2009-03-31
JP5921910B2 (ja)	2016-05-24
CR8998A (es)	2007-11-23
SV2006002211A (es)	2006-10-04
EG26922A (en)	2014-12-25
IL181588A0 (en)	2007-07-04
UA89383C2 (ru)	2010-01-25
HK1121497A1 (en)	2009-04-24
SI1781802T1 (sl)	2010-01-29
CY1110092T1 (el)	2015-01-14
EP1992697B1 (de)	2010-03-17
NZ579208A (en)	2012-01-12
AU2005280036A1 (en)	2006-03-09
RS51072B (sr)	2010-10-31
KR100988451B1 (ko)	2010-10-18
TWI364458B (en)	2012-05-21
ECSP077354A (es)	2007-05-30
US7300773B2 (en)	2007-11-27
MX2007002381A (es)	2007-06-15
DK1781802T3 (da)	2010-01-25
BRPI0514694B1 (pt)	2019-04-24
GT200500234A (es)	2006-10-10
PT1781802E (pt)	2010-01-04
CY1109721T1 (el)	2014-08-13
CA2578138C (en)	2010-10-05
ES2341390T3 (es)	2010-06-18
GT200500233A (es)	2006-03-09
AR050537A1 (es)	2006-11-01
EP1781802A2 (de)	2007-05-09
TW200619388A (en)	2006-06-16
NO344785B1 (no)	2020-04-27
JP2016056214A (ja)	2016-04-21
WO2006026447A2 (en)	2006-03-09
WO2006026447A9 (en)	2006-06-01
PE20100448A1 (es)	2010-06-22
AU2005280036B2 (en)	2011-11-03
EP1781802B1 (de)	2009-10-21
JP2008511330A (ja)	2008-04-17
IL181588A (en)	2010-12-30
PE20060815A1 (es)	2006-09-14
HK1099941A1 (en)	2007-08-31
BRPI0514694A (pt)	2008-06-17
HN2005000485A (es)	2009-06-09
EP1992697A1 (de)	2008-11-19
SI1992697T1 (sl)	2010-07-30
PT1992697E (pt)	2010-04-21
DE602005017285D1 (de)	2009-12-03
RU2458988C2 (ru)	2012-08-20
NO20071570L (no)	2007-05-23
CR20120560A (es)	2012-12-04
CN101061231B (zh)	2012-09-26
AR088824A2 (es)	2014-07-10
RU2007108717A (ru)	2008-10-10
CN101061231A (zh)	2007-10-24
RS51255B (sr)	2010-12-31
PL1992697T3 (pl)	2010-08-31
KR20070069140A (ko)	2007-07-02
HRP20100271T1 (hr)	2010-06-30
CL2017000577A1 (es)	2017-12-01
WO2006026447A3 (en)	2006-04-20
ES2335518T3 (es)	2010-03-29
PL1781802T3 (pl)	2010-03-31

Legal Events

Date

Code

Title

Description

2011-03-10

8363

Opposition against the patent

2012-06-05

R082

Change of representative

Ref document number: 1992697

Country of ref document: EP

Representative=s name: REITSTOETTER, KINZEBACH & PARTNER (GBR), DE

Publication	Publication Date	Title
ATE461285T1 (de)	2010-04-15	Herstellung von tnfr-fc
DE602005018076D1 (de)	2010-01-14	Enantioselektive herstellung von chinolin-derivaten
DE502006009254D1 (de)	2011-05-19	Herstellung von natriumdiformiat
FI20041059A0 (fi)	2004-08-05	Komponentin sisältävän kerroksen valmistaminen
DE602005011285D1 (de)	2009-01-08	Formmasse von polymer
DE602007014179D1 (de)	2011-06-09	Herstellung von polytrimethylen-etherglykol
DE602006006861D1 (de)	2009-06-25	Herstellung von polytrimethylenetherglykol und copolymeren davon
DE602006006710D1 (de)	2009-06-18	Herstellung von polytrimethylenetherglykol und copolymeren davon
NO20043305D0 (no)	2004-08-09	Preparation of lodixanol
DE602004029836D1 (de)	2010-12-16	Herstellung von Turbinenelementen
DE602004013599D1 (de)	2008-06-19	Herstellung von somatostatinpeptiden
DE602004022046D1 (de)	2009-08-27	Herstellung von kleinen teilchen
DE602004003529D1 (de)	2007-01-18	Herstellung von Organohalosilanen
DE60307022D1 (de)	2006-09-07	Herstellung von Organohalosilanen
SE0601411L (sv)	2006-06-28	Förfarande vid beredning
FI20041385A0 (fi)	2004-10-27	Symmetria-akselin määrittäminen
DE602005026641D1 (de)	2011-04-14	Neue 1-methoxy-2-phenylethene zur herstellung von 5-carboxaldehyd-2,3-dihydrobenzoxepinen
SE0403090D0 (sv)	2004-12-20	Framställning av häften
ES1058948Y (es)	2005-06-16	Helice
DE502004006136D1 (de)	2008-03-20	Verrastung von Baugruppen
FI20041228A (fi)	2006-03-24	Hiomakiven kunto
FI20040640A0 (fi)	2004-05-06	Ruukku tai sen kaltainen
SE0403161L (sv)	2006-06-24	Ny användning av glucosine
DE602004009544D1 (de)	2007-11-29	Neue 3,3-Dimethyl-5-Cyano-Benzoxepinderivate verwendbar zur Herstellung von 5-Formyl-Benzoxepinderivaten
NO20042454D0 (no)	2004-06-11	Novel fish virus